Kyverna Therapeutics, Inc. business relationships
Companies named in Kyverna Therapeutics, Inc.’s 10-K filed 2026-03-26, and public companies whose annual reports name Kyverna Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 4 / 100 Top 3% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Kyverna Therapeutics, Inc.’s annual report 2
“In January 2020, the Company entered into the Collaboration, Option and License Agreement (the "Gilead Agreement") with Gilead Sciences, Inc. ("Gilead").” SEC filing
“In December 2021, the Company entered into a License and Collaboration Agreement (the "Intellia Agreement") with Intellia Therapeutics, Inc. ("Intellia") to research and develop an allogeneic CD19-directed CAR cell therapy product (the "CRISPR Product"), suitable for validation through pre-clinical...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.